Cartesian Therapeutics (RNAC) Return on Equity (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, down 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 2.0% YoY), and the FY2025 annual result was 0.02%, up 2.0% from the prior year.
• Return on Equity fell to 0.01% in Q1 2026 per RNAC's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Equity peaked at 0.12% in Q4 2024 and troughed at 0.01% in Q3 2023.
• A 5-year average of 0.02% and a median of 0.01% in 2026 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2024 and 2025: Return on Equity advanced 11 bps in 2024, then retreated 10 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then jumped by 430 bps to 0.01% in 2023, then soared by 849 bps to 0.12% in 2024, then slumped by 86 bps to 0.02% in 2025, then tumbled by 39 bps to 0.01% in 2026.
• Business Quant data shows RNAC's Return on Equity at 0.01% in Q1 2026, 0.02% in Q4 2025, and 0.04% in Q3 2025.